Clinical trials in Rome – page 177

In Roma, a large share of recruiting studies focuses on hematologic malignancies and related blood disorders, with research spanning leukemia, lymphoma, myelodysplastic syndromes, and myelofibrosis. These trials are mainly designed to test new treatment combinations, improve disease control, and deepen understanding of measurable disease response.

• Acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myeloid leukemia
• Follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma
• Myelodysplastic syndromes, myelofibrosis, anemia linked to marrow disease, and transplant-related settings
• Studies often aim to improve remission rates, reduce residual disease, or extend survival

This is a strong area of research activity across multiple research sites in the city, reflecting a broad effort to refine modern blood cancer care.

Another major focus is neoplasms, especially breast cancer, colorectal cancer, head and neck cancer, and other advanced solid tumors. The trials are generally aimed at improving survival, increasing response to treatment, and identifying more effective therapeutic sequences.

• Early and metastatic breast cancer, including hormone receptor-positive and triple-negative disease
• Metastatic colorectal cancer, rectal cancer, and high-risk colon cancer
• Recurrent or metastatic head and neck squamous cell carcinoma and other difficult-to-treat tumors
• Research commonly tests new drug combinations and personalized treatment strategies

Several studies also explore biomarkers and treatment adaptation to better match therapy with tumor biology.

Immune system diseases and chronic inflammatory conditions form another important part of the trial landscape. Research in this area includes autoimmune, allergic, and inflammatory disorders, with a focus on easing symptoms, maintaining disease control, and improving long-term safety.

• Psoriatic arthritis, plaque psoriasis, and atopic dermatitis
• Crohn’s disease and chronic inflammatory demyelinating polyneuropathy
• Hereditary angioedema and inflammatory cardiomyopathy
• Many trials are evaluating better symptom control and sustained treatment benefit

These studies highlight a growing interest in targeted immune-modulating therapies for both skin and systemic inflammatory disease.

Cardiovascular diseases are also well represented, particularly in patients with coronary disease, heart failure-related inflammation, and amyloid-related cardiac conditions. The main goal is to improve safety and clinical outcomes while reducing complications linked to long-term treatment.

• Atrial fibrillation after PCI and broader antithrombotic treatment questions
• Inflammatory cardiomyopathy and severe cardiac inflammation
• Transthyretin cardiac amyloidosis
• Trials are often assessing better balance between protection from events and bleeding risk

This area combines prevention, treatment optimization, and symptom management for patients with complex heart disease.

Research in nervous system diseases includes both neurological and neuropsychiatric conditions. The studies aim to improve symptom control, evaluate new treatment options, and support longer-term tolerability in chronic disorders.

• Psychosis associated with Alzheimer’s disease
• Chronic inflammatory demyelinating polyneuropathy
• Trials focus on treatment effectiveness, safety, and sustained control of symptoms

These projects reflect an effort to address conditions that can strongly affect independence and quality of life.

A notable group of studies addresses nutritional and metabolic diseases as well as kidney and hormone-related disorders. The research is aimed at slowing progression, improving biochemical control, and easing treatment burden for chronic conditions.

• Autosomal dominant polycystic kidney disease and IgA nephropathy
• Hypoparathyroidism, obesity, and propionic acidemia
• Trials seek to improve organ function, calcium balance, and metabolic stability
• Some studies compare existing standards with newer treatment approaches

This field shows a mix of rare-disease research and more common chronic metabolic care.

Several studies in bacterial infections and mycoses and virus diseases focus on preventing or treating infection, including work in surgical and urinary settings. The purpose is to reduce complications, improve recovery, and support more efficient antibiotic use.

• Urinary tract infections and postoperative incisional infection prevention
• HIV treatment optimization in virologically suppressed patients
• Research also includes strategies for improving infection control after surgery

These trials are clinically practical, with a clear focus on safer care and better patient outcomes.

Skin and connective tissue diseases are represented by studies on chronic inflammatory skin conditions and difficult-to-heal wounds. The main research goal is to improve healing, reduce lesion burden, and strengthen everyday symptom relief.

• Atopic dermatitis and moderate-to-severe psoriasis
• Venous leg ulcers and wound bed preparation
• Studies are testing more effective symptom control and better tissue repair

This area combines dermatologic care with wound-management research relevant to both specialists and patients.

Trials in digestive system diseases address inflammatory bowel disease, bile acid diarrhoea, and colorectal conditions. Researchers are working to improve symptom relief, support healing, and refine treatment choices for persistent gastrointestinal problems.

• Crohn’s disease and bile acid diarrhoea
• Rectal cancer and colon cancer
• Some studies examine better disease control and organ-preserving treatment approaches

The work in Roma reflects both common gastrointestinal care and more specialized oncologic research.

A smaller but important portion of the portfolio covers congenital, hereditary, and neonatal diseases, with a focus on rare inherited disorders. These trials aim to improve disease control, support organ preservation, and expand treatment options where choices are limited.

• Propionic acidemia
• Hereditary angioedema and autosomal dominant polycystic kidney disease
• Research often explores new therapies for symptom prevention and long-term disease management

This area is especially relevant for patients living with uncommon conditions that require specialized care.

Male and female urogenital diseases appear in studies on urinary tract infections, urothelial cancer, and pregnancy-related complications, alongside cancer-focused work. The goal is generally to improve treatment effectiveness while reducing recurrence or complications.

• Low-grade upper tract urothelial cancer and urinary tract infections
• Some studies also involve renal and reproductive health-related conditions
• Trial aims include better tumor control, infection management, and safer treatment options

These trials add breadth to the city’s research profile beyond hematology and solid tumors.

Musculoskeletal diseases are represented through inflammatory joint disease research, especially in conditions that affect daily mobility and function. The studies are mainly designed to ease inflammation, improve function, and compare treatment strategies.

• Psoriatic arthritis
• Focus on symptom relief and better control of joint inflammation
• Comparisons often center on established therapies versus newer targeted approaches

This field complements the broader immune-mediated disease research seen across the city.

A smaller set of studies in analytical, diagnostic and therapeutic techniques and equipment supports broader clinical research by improving how conditions are monitored and treated. The emphasis is on practical innovation, better decision-making, and treatment support across multiple disease areas.

• Research tools that help assess response, safety, or disease burden
• Technique-focused studies linked to cancer, cardiovascular, and surgical care
• Purpose is usually to make treatment delivery or evaluation more effective

This work strengthens the overall trial environment by supporting more precise and efficient clinical care.